US-based Boston Scientific Corporation (NYSE: BSX) has announced the official market launch of its Expect airway ultrasound needle in mainland China. The product is designed for use in transbronchial needle aspiration biopsies guided by endoscopic ultrasonography, offering a significant advancement in lung cancer diagnosis.
Product Innovation and Advantages
The Expect airway ultrasound needle integrates ultrasound technology within an endoscope, allowing operators to perform minimally invasive, accurate, and safe biopsies under direct ultrasound vision. This system enables the sampling of lymph node or tumor tissue with high sensitivity and diagnostic accuracy. The unique cobalt-chromium needle design reduces wall thickness while maintaining robustness, ensuring sufficient tissue samples for cancer diagnosis and staging.
Clinical Evidence and Impact
Clinical evidence demonstrates that the tissue samples obtained using this needle have fewer blood cells and higher quality compared to traditional methods. The sensitivity, specificity, and negative predictive value of the Expect airway ultrasound needle are comparable to those of mediastinoscopy, a more invasive procedure. This convenience and accuracy are expected to elevate the standard of clinical lung cancer diagnosis and treatment in China.-Fineline Info & Tech
